Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19

Leukemia · April 2020

Asnani M, Hayer KE, Naqvi AS, Zheng S, Yang SY, Oldridge D, Ibrahim F, Maragkakis M, Gazzara MR, Black KL, Bagashev A, Taylor D, Mourelatos Z, Grupp SA, Barrett D, Maris JM, Sotillo E, Barash Y, Thomas-Tikhonenko A

Summary

This study identifies intron 2 retention in CD19 transcripts as a mechanism contributing to CAR-T19 therapy resistance in leukemias harboring subclonal frameshift mutations in CD19. The findings reveal how alternative splicing can undermine antigen-targeted cancer immunotherapy.

Summary#

Summary